ASXL1 and systemic mastocytosis: Studies have shown that patients with advanced SM, age > 60 years, Hb < 10 g/dL, transfusion dependence, platelet < 150 × 109/L, serum albumin < 3.5 g/dL, and mutation in ASXL1 were each associated with inferior survival in multivariate analysis [17].